Abstract
Exenatide QW is a depot form, in which the molecule of exenatide is incorporated into the microspheres, from which its own active substance is released very slowly after subcutaneous application. When applied once weekly (OW), the therapeutic concentration is achieved after three submissions.
The steady state is achieved usually after 6 to 7 weeks. Clinical efficacy of exenatide QW was evaluated in a series of clinical trials called DURATION.
Exenatide QW showed a good clinical efficacy and a low risk of hypoglycemia, constant weight loss, reduced incidence of dyspeptic disorders, minimum incidence of adverse effects. It is a great expansion of the portfolio of antidiabetic pharmaceuticals.